FDA Approved: XCOPRI — Supplemental Application (SK Life Science, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for XCOPRI (cenobamate) submitted by SK Life Science, Inc., resulting in updated labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Focal Onset Seizures

Drugs mentioned

• Xcopri (cenobamate)

Snippet

SUPPL AP for XCOPRI (CENOBAMATE)